Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2026 | $48.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/5/2026 | $41.00 | Neutral → Underperform | BofA Securities |
| 11/18/2025 | Peer Perform | Wolfe Research | |
| 11/3/2025 | Buy → Neutral | Guggenheim | |
| 10/21/2025 | $48.00 | Market Perform → Outperform | Leerink Partners |
| 9/19/2025 | $40.00 | Equal Weight | Barclays |
| 9/17/2025 | $40.00 | Equal Weight | Barclays |
| 9/17/2025 | $47.00 | Buy | Goldman |
DEFA14A - EXELIXIS, INC. (0000939767) (Filer)
DEFA14A - EXELIXIS, INC. (0000939767) (Filer)
DEF 14A - EXELIXIS, INC. (0000939767) (Filer)
Morgan Stanley downgraded Exelixis from Overweight to Equal-Weight and set a new price target of $48.00
BofA Securities downgraded Exelixis from Neutral to Underperform and set a new price target of $41.00
Wolfe Research initiated coverage of Exelixis with a rating of Peer Perform
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event
- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 46th Annual Health Care Conference: Exelixis is scheduled to present at 1:10 p.m. ET / 10:10 a.m. PT on Tuesday, March 3 in Boston. Leerink Partners 2026 Global Healthcare Conference: Exelixis is scheduled to present at 10:40 a.m. ET / 7:40 a.m. PT on Tuesday, March 10 in Miami. 2026 Citizens Life Sciences Conference: Exelixis is scheduled to present at 9:35 a.m. ET / 6:35 a.m. PT on Wednesday, March 11 in Miami. Barclays 28th Annual Global Healthcare Conference: Exel
– Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – – Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quarter of 2025 – – GAAP Diluted EPS of $0.88 for the Fourth Quarter of 2025, $2.78 for the Fiscal Year 2025 – – Conference Call and Webcast Today at 5:00 PM Eastern Time – Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis deli
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-12) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/17/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)
SC 13G - EXELIXIS, INC. (0000939767) (Subject)
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event
– Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – – Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quarter of 2025 – – GAAP Diluted EPS of $0.88 for the Fourth Quarter of 2025, $2.78 for the Fiscal Year 2025 – – Conference Call and Webcast Today at 5:00 PM Eastern Time – Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis deli
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com a
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man
– Dr. Aftab has served for over 25 years at Exelixis and has been instrumental in driving the company's scientific innovation and development activities – Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company's drug discovery, translational research, product development and medical affairs activities. "Dana has been an integral part of the Exelixis team for more than 25 years, with deep expertise that spans the drug discovery and development continuum. He's been a key contributor to many of Exelixis' most important milestones, inclu
Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo